Prospect: information for the user
Donepezilo Flas Pharma Combix 10 mg buccal dispersible tablets EFG
Donepezilo,hydrochloride
Read this prospect carefully before starting to take this medicine, as it contains important information for you.
1.What is Donepezilo Flas Pharma Combix and for what it is used
2.What you need to know before taking Donepezilo Flas Pharma Combix
3.How to take Donepezilo Flas Pharma Combix
4.Possible adverse effects
5.Storage of Donepezilo Flas Pharma Combix
6.Contents of the package and additional information
Donepezilo FlasPharmaCombix(hdonepezilo hydrochloride) belongs to a group of medicines called acetylcholinesterase inhibitors. Donepezilo hydrochloride increases the levels in the brain of a substance related to memory (acetylcholine), by reducing the rate of breakdown of this substance.
It is used for the treatment of the symptoms of mild to moderately severe Alzheimer's disease. The symptoms include increased loss of memory, confusion, and changes in behavior.
Do not take Donepezilo Flas Pharma Combix
Warnings and precautions
Consult your doctor or pharmacist before starting to take Donepezilo Flas Pharma Combix if you have or have had:
You should avoid taking this medication with other acetylcholinesterase inhibitors and other cholinergic agonists or antagonists.
Taking Donepezilo Flas Pharma Combix with other medications
Inform your doctor or pharmacist if you are taking or have taken recently or may have to take any other medication, especially if you are taking any of the following medications:
In the event of surgical intervention with general anesthesia, you should inform your doctor that you are taking donepezilo tablets because this may affect the amount of anesthetic needed.
Donepezilo tablets may be used in patients with mild to moderate kidney or liver disease. Inform your doctor if you have any kidney or liver disease. Patients with severe liver disease should not take donepezilo tablets.
Taking Donepezilo Flas Pharma Combix with food, drinks, and alcohol
Place the tablet on the tongue and let it dissolve. Swallow with or without water.
Donepezilo tablets should not be taken with alcohol as alcohol may modify the effect of this medication.
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, or think you may be pregnant, or intend to become pregnant, consult your doctor or pharmacist before using this medication.
Do not take donepezilo tablets if you are pregnant or think you may be pregnant.
Do not take donepezilo tablets if you are breastfeeding your child.
Driving and operating machinery
Your condition may affect your ability to drive or operate machinery and you should not engage in these activities unless your doctor tells you it is safe to do so. Donepezilo tablets may cause dizziness and drowsiness, mainly at the start of treatment or when increasing the dose. If you experience these effects, you should not drive or operate machinery.
Donepezilo Flas Pharma Combix contains aspartame
This medication may be harmful to people with phenylketonuria because it contains aspartame, which is a source of phenylalanine.
Donepezilo Flas Pharma Combix contains glucose
This medication contains glucose. If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medication.
Follow exactly the administration instructions for this medication as indicated by your doctor. In case of doubt, consult your doctor or pharmacist again.
Donepezilo buccodispersible tablets are administered orally. The tablet should be placed on the tongue and allowed to dissolve before swallowing with or without water.
Treatment with donepezilo buccodispersible tablets begins with a 5 mg tablet, taken once a day, at night, immediately before going to bed. After a month of treatment, your doctor may recommend an increase in the dose to 10 mg, taken once a day and at night. The maximum recommended dose is 10 mg per day.
If you experience abnormal dreams, nightmares, or difficulty sleeping (see section 4), your doctor may recommend taking Donepezilo Flas Pharma Combix in the morning.
If you have mild or moderate liver disease (a disease that affects the liver) or renal insufficiency (a disease that affects the kidneys), you can take donepezilo buccodispersible tablets. Inform your doctor before starting treatment if you have liver or kidney problems. Patients with severe liver disease should not take donepezilo buccodispersible tablets.
Use in children
Donepezilo buccodispersible tablets are not recommended for use in children.
If you take more Donepezilo Flas Pharma Combix than you should
If you have taken more donepezilo buccodispersible tablets than you should, consult your doctor, pharmacist, or call the Toxicological Information Service, phone: 91 562 04 20, indicating the medication and the amount used.
The symptoms of overdose may include feeling unwell, drooling, sweating, decreased heart rate, low blood pressure (dizziness or dizziness when standing up), breathing difficulties, loss of consciousness, and seizures.
If you forget to take Donepezilo Flas Pharma Combix
Do not take a double dose to compensate for the missed doses.
If you interrupt treatment with Donepezilo Flas Pharma Combix
Do not stop taking donepezilo buccodispersible tablets unless your doctor tells you to. If you stop taking donepezilo buccodispersible tablets, the benefits of treatment will gradually disappear.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
The following side effects have been reported by people taking donepezil buccal tablets.
Contact your doctor if you experience any of these side effects during treatment with donepezil buccal tablets.
Severe side effects:
You should inform your doctor immediately if you notice any of the following severe side effects mentioned, as you may need urgent medical treatment.
The estimated frequency of side effects is as follows:
Very common: may affect more than 1 in 10 people
Common: may affect up to 1 in 10 people
Uncommon: may affect up to 1 in 100 people
Rare: may affect up to 1 in 1,000 people
Frequency not known:
Reporting side effects
If you experience any type of side effect, consult your doctor or pharmacist. Even if it is a possible side effect that does not appear in this leaflet, you can also report it directly through the Spanish System for the Vigilance of Medicines for Human Use:https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the blister pack and on the case after CAD. The expiration date is the last day of the month indicated.
This medication does not require special storage conditions.
Medications should not be disposed of through drains or in the trash. Dispose of the packaging and medications you no longer need at the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medications you no longer need. By doing so, you will help protect the environment.
Composition of Donepezilo FlasPharmaCombix
Appearance of the product and contents of the package
Donepezilo FlasPharmaCombix 10 mg is presented in buccal dispersible tablets, i.e., that dissolve in the mouth. The tablets are yellow to pale yellow, round, with beveled edges, smooth on both faces.
Donepezilo FlasPharmaCombix10 mg buccal dispersible tablets are presented in Alu/Alu blister packs. Each package contains 28 or 56 buccal dispersible tablets.
Only some package sizes may be commercially available.
Marketing Authorization Holder
Combix, S.L.U.
C/Badajoz, 2. Edificio 2
28223 Pozuelo de Alarcón (Madrid)
Spain
Responsible for manufacturing
Zydus France
ZAC Les Hautes Patures
Parc d'activités des Peupliers
25 Rue des Peupliers
92000 Nanterre
France
or
Centre Spécialités Pharmaceutiques
ZAC des Suzots
35 rue de la Chapelle
63450 Saint Amant Tallende
France
Last review date of this leaflet:November 2022
The detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/.
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.